Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.Av The Lancet

Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.Av The Lancet

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.Av The Lancet

Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy.Av The Lancet

Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS.Av The Lancet

Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease.Av The Lancet

Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa.Av The Lancet

Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake.Av The Lancet

Louise Dye (University of Leeds) discusses a trial exploring the role of expectancy and gluten ingestion on symptoms in people with non-coeliac gluten sensitivity.Av The Lancet

Tzu-Chan Hong (National Taiwan University Cancer Centre) discusses a systematic review and meta-analysis on primary antibiotic resistance of Helicobacter pylori between 1990 and 2022 in the Asia-Pacific region.Av The Lancet

Sarah Moen (Erasmus University Medical Center) discusses a retrospective cohort study examining the risk of metachronous colorectal cancer after partial or extensive colectomy in carriers of different pathogenic Lynch syndrome variants.Av The Lancet

Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease.Av The Lancet

Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction.Av The Lancet

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.Av The Lancet

Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease.Av The Lancet

Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis.…

Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender.Av The Lancet

Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings.Av The Lancet

Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.Av The Lancet

Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma.Av The Lancet

Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.Av The Lancet

Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection.Av The Lancet

James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease.Av The Lancet

Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea.Av The Lancet

Edward Kim (Icahn School of Medicine at Mount Sinai) discusses the single-arm RASER study of radiation segmentectomy for patients with unresectable very early to early stage hepatocellular carcinoma.Av The Lancet

Joep Ijspeert (Amsterdam University Medical Center) discusses a population-based study exploring the detection of proximal serrated polyps and interval post-colonoscopy colorectal cancer risk.Av The Lancet

Elise Meima-van Praag (Amsterdam University Medical Centre) discusses the PISA-II trial, investigating short-term anti-TNF therapy with surgical closure versus anti-TNF therapy for perianal fistulas in Crohn's disease.Av The Lancet

Juan Pablo Arab (Catholic University of Chile) discusses the current burden of NAFLD and the landscape of public health policies related to the disease in the Americas.Av The Lancet

Sarah Blach (CDA Foundation) summarises the latest analysis of global hepatitis C virus epidemiology and cascade of care by the Polaris Observatory HCV Collaborators.Av The Lancet

Sunil Solomon (Johns Hopkins University) discusses a study of a minimal monitoring approach for treating patients with hepatitis C virus infection.Av The Lancet

Rupert Leong (University of Sydney) discusses a new double-blind, randomised, placebo-controlled trial of oral faecal microbiota transplantation for patients with active ulcerative colitis.Av The Lancet

Swati Patel (University of Colorado Anschutz Medical Center) discusses the epidemiology, clinical features, biology, risk factors, and opportunities for prevention and detection of early-onset colorectal cancers.Av The Lancet

Emilie Breekveldt (Erasmus Medical Center, Netherlands) discusses a new analysis of the faecal immunochemical testing-based colorectal screening programme in the Netherlands.Av The Lancet

Wendy Spearman (University of Cape Town) discusses a Series on the emergence of non-alcoholic fatty liver disease in Sub-Saharan Africa and the challenges it presents.Av The Lancet

Tim Vanuytsel (University of Leuven) discusses a new trial of spore-forming probiotics in functional dyspepsia.Av The Lancet

Raymond Henderson (Queen’s University Belfast) discusses a new analysis of the economic burden of colorectal cancer in Europe.Av The Lancet

Sigurður Ólafsson (Landspitali University Hospital) discusses newly published results from the nationwide programme to eliminate hepatitis C virus in Iceland.Av The Lancet

Caroline Ovadia (King’s College London) discusses an individual participant data meta-analysis on the treatment of intrahepatic cholestasis of pregnancy with ursodeoxycholic acid.Av The Lancet

Matthew Akiyama (Montefiore Medical Center and Albert Einstein College of Medicine, USA) discusses a Review on hepatitis C elimination among people incarcerated in prisons.Av The Lancet

Monika Sarkar (University of California San Francisco, USA) discusses her Comment on reproductive health in women with chronic liver disease.Av The Lancet

Ola Olén discusses the assesment of colorectal cancer risk in patients with Crohn's disease.Av The Lancet

Av The Lancet

Marc Rothenberg joins The Lancet Gastroenterology & Hepatology to talk about eosinophilic oesophagitis endotype classification.Av The Lancet

Dr Kushala Abeysekara discusses research looking at the prevalence of non-alcoholic fatty liver disease in young adults in England.Av The Lancet

Professor Alexander Ford discusses a meta analysis comparing different traditional treatments for irritable bowel syndrome.Av The Lancet

Dr. Elisa Pose discusses the potential beneficial effects of statins on the treatment of patients with decompensated cirrhosisAv The Lancet

Mohsen Naghavi describes the key findings from two new Global Burden of Disease studies investigating the global burden of pancreatic cancer and colorectal cancer.Av The Lancet

Viktor Wintzell joins The Lancet Gastroenterology & Hepatology to discuss the risk of serious infection after use of tumour necrosis factor-α inhibitors in children with inflammatory bowel disease.Av The Lancet

Prof Raymond Chung discusses new research in transplantation of HCV-infected hearts.Av The Lancet

Daniel Lambrichts joins The Lancet Gastroenterology & Hepatology to discuss different treatments for diverticulitis.Av The Lancet